WHITE PAPER
Championing Oncology Relevant Endpoints (CORE) in Canada
Surrogate endpoints in clinical trials and reimbursement decisions for early-stage cancers
Feb 20, 2023
Download

The research presented in this paper was conducted by the Oncology Real World Solutions team at IQVIA Canada and was sponsored by AstraZeneca Canada. AstraZeneca and IQVIA partnered through project CORE (Championing Oncology Relevant Endpoints) which aims to expand the acceptability of oncology relevant endpoints by regulatory authorities, HTA agencies and payers in Canada within the solid tumour space.

Related solutions

Contact Us